Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Donald G. Archibald"'
Autor:
Larry Alphs, Paul McSorley, Christy Chuang-Stein, Donald G. Archibald, Michael J. Detke, Jeffrey H. Schwartz, David G.S. Perahia, Craig H. Mallinckrodt
Publikováno v:
Pharmaceutical Statistics. 6:9-22
Assessing long-term efficacy in psychiatric drugs involves a number of complex questions, and the priaority of these questions is different for different disorders and for different stakeholders. Therefore, it is essential that we not adopt a one-met
Autor:
Donald G. Archibald, Andrew C. Leon, Kevin Chartier, Craig H. Mallinckrodt, Graeme Archer, Christy Chuang-Stein
Publikováno v:
Biological Psychiatry. 59:1001-1005
Attrition is a ubiquitous problem in randomized controlled clinical trials (RCT) of psychotropic agents that can cause biased estimates of the treatment effect, reduce statistical power, and restrict the generalizability of results. The extent of the
Autor:
A. Saha, Teresa A. Pigott, William H. Carson, Gary G. Ingenito, Siegfried Kasper, Robert D. McQuade, Mirza Ali, Donald G. Archibald, Ronald N. Marcus, Mark N. Lerman
Publikováno v:
The International Journal of Neuropsychopharmacology. 6:325-337
Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of
Publikováno v:
The American Journal of Cardiology. 83:354-359
Women are at increased risk for torsades de pointes associated with a variety of drugs that prolong ventricular repolarization, but few data exist regarding possible sex differences in extent of repolarization changes with these medications.We sought
Autor:
Donald G. Archibald, Ronald N. Marcus, W. Wolfgang Fleischhacker, Rene Swanink, Robert D. McQuade, William H. Carson
Publikováno v:
Biological psychiatry. 65(6)
Few studies have directly compared the efficacy and tolerability of atypical agents.This multicenter, randomized, double-blind study compared the efficacy and tolerability of aripiprazole (n = 355) with olanzapine (n = 348) in patients with schizophr
Autor:
Charles S. Wilcox, Stephen Kaplita, Douglas L. Roberts, Robert J. Bielski, Donald G. Archibald, Madhukar H. Trivedi, James Bremner, Robert D. McQuade, Alan D. Feiger, Terry T. Kensler, Jon F. Heiser
Publikováno v:
International clinical psychopharmacology. 14(1)
The efficacy of nefazodone in prevention of relapse of depression was evaluated in a 36-week double-blind, placebo-substitution, continuation treatment trial. After 16 weeks of acute, single-blind treatment with nefazodone, 131 patients responding to
Publikováno v:
Circulation. 94(10)
Background The present study was undertaken to test the hypothesis that women are more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients exposed to the QT-prolonging antiarrhythmic drug d,l -sotalol. Methods and Resul
Autor:
Mary J. Kujawa, William H. Carson, Ronald N. Marcus, Donald G. Archibald, Christopher D. Breder, Yasuchika Yamamoto, Dusan Kostic, Taro Iwamoto
Publikováno v:
Neurobiology of Aging. 25:S183
Autor:
Donald G. Archibald, Joseph C. Stringfellow, Stephen W. Jenkins, Donald S. Robinson, Patrick J. McGrath, Jonathan W. Stewart, Frederic M. Quitkin, Stephen Wager
Publikováno v:
Journal of Clinical Psychopharmacology. 14:347
This is a report of a controlled trial of gepirone, a 5-hydroxytryptamine (5-HT1A) partial agonist azapirone related to buspirone, in the treatment of atypical depression. The azapirones are of particular interest because their highly selective actio
Autor:
W E Steinke, M M LeWinter, J W Davis, S C Sabharwal, H W Schnaper, H D Lewis, E Linares, T C Smitherman, J E Doherty rd, Donald G. Archibald, J M Pouget, E Chesler, H DeMots
Publikováno v:
New England Journal of Medicine. 309:396-403
We conducted a multicenter, double-blind, placebo-controlled randomized trial of aspirin treatment (324 mg in buffered solution daily) for 12 weeks in 1266 men with unstable angina (625 taking aspirin and 641 placebo). The principal end points were d